U.S. markets close in 6 hours 13 minutes
  • S&P 500

    4,142.82
    -45.61 (-1.09%)
     
  • Dow 30

    34,413.95
    -328.87 (-0.95%)
     
  • Nasdaq

    13,234.55
    -167.30 (-1.25%)
     
  • Russell 2000

    2,164.00
    -48.70 (-2.20%)
     
  • Crude Oil

    64.25
    -0.67 (-1.03%)
     
  • Gold

    1,823.00
    -14.60 (-0.79%)
     
  • Silver

    27.32
    -0.18 (-0.64%)
     
  • EUR/USD

    1.2165
    +0.0031 (+0.26%)
     
  • 10-Yr Bond

    1.6270
    +0.0250 (+1.56%)
     
  • GBP/USD

    1.4135
    +0.0013 (+0.09%)
     
  • USD/JPY

    108.5570
    -0.2840 (-0.26%)
     
  • BTC-USD

    55,339.77
    -2,404.04 (-4.16%)
     
  • CMC Crypto 200

    1,568.13
    +1,325.45 (+546.17%)
     
  • FTSE 100

    6,932.80
    -190.88 (-2.68%)
     
  • Nikkei 225

    28,608.59
    -909.71 (-3.08%)
     

Fate Therapeutics: Q4 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Fate Therapeutics (NASDAQ:FATE) were flat in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share fell 64.86% over the past year to ($0.61), which missed the estimate of ($0.39).

Revenue of $15,896,000 higher by 467.31% from the same period last year, which beat the estimate of $4,870,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Feb 24, 2021

View more earnings on FATE

Time: 05:00 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/kficf9ki

Price Action

52-week high: $121.16

52-week low: $16.75

Price action over last quarter: Up 97.33%

Company Profile

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.